StemCyte-KY: Significant US Subsidiary StemCyte, Inc. Board Approves Cash Capital Increase

1. Date of the board of directors resolution: June 17, 2026 2. Source of capital increase funds: Cash capital increase 3. Whether adopting shelf registration for issuing new shares (If yes, please specify the expected issuance period / No): No 4. Total issuance amount and number of shares for this case (If it is capital increase from retained earnings or capital reserve, the issued shares do not include those distributed to employees): Total issuance amount is USD 4,732,000 5. For shelf registration issuance of new shares, the current issuance amount and number of shares: Not applicable 6. For shelf registration issuance of new shares, the remaining amount and balance of shares after this issuance: Not applicable 7. Par value per share: USD 0.001 8. Issue price: Not applicable 9. Number of shares subscribed or amount allocated to employees: Not applicable 10. Number of shares for public offering: Not applicable 11. Proportion of subscription or gratuitous allocation to original shareholders: 100% subscribed by the parent company, StemCyte Inc. 12. Handling method for fractional shares and overdue unsubscribed shares: Not applicable 13. Rights and obligations of the newly issued shares: Same as the original shares. 14. Purpose of the funds from this capital increase: To replenish working capital. 15. Reasonableness and necessity of raising funds after capital reduction by cash (Applicable to cases where capital reduction by cash was carried out in the current or preceding year of fundraising): Not applicable 16. Other matters requiring clarification: Approved by the board of directors of the US subsidiary StemCyte, Inc. on June 16, 2026 (US time).